Jennifer Christy Alyono, MD
Otolaryngology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Alyono’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A123854 · Current
Licensed to practise in California · since 2012 · expires 2028-10-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$75,760
Medicare paid this office $75,760 for 276 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Insertion of cochlear device | 15 | $17,184 | $1,146 |
| Short return visit (20+ min) | 132 | $10,812 | $56 |
| Return visit (30+ min) | 85 | $8,691 | $87 |
| New patient visit (45+ min) | 68 | $6,975 | $103 |
| New patient visit (30+ min) | 36 | $2,473 | $69 |
Who their Medicare patients are
276 Original Medicare patients in 2024. Average age 73 · Under 65 9% · 85 and older 12% · Women 53% · Also on Medicaid 24% · Health risk score 1.43. Above the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 67% · Coronary heart disease 26% · Diabetes 25% · Chronic kidney disease 22% · Cancer 16% · Depression 16% · Atrial fibrillation 14% · Heart failure 13% · COPD 11% · Stroke 11% · Dementia 5%.
The office billed $502,696, Medicare allowed $99,125 and paid $75,760; for 492 services of 42 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 276 | 492 | 73 | 1.43 | $502,696 | $75,760 |
| 2023 | 255 | 444 | 74 | 1.22 | $361,372 | $66,420 |
| 2022 | 249 | 431 | 74 | 1.28 | $336,311 | $60,315 |
| 2021 | 243 | 564 | 73 | 1.30 | $358,190 | $70,410 |
| 2020 | 228 | 519 | 73 | 1.40 | $264,986 | $46,666 |
| 2019 | 227 | 461 | 72 | 1.48 | $301,330 | $51,326 |
| 2018 | 66 | 101 | 71 | 1.27 | $79,965 | $11,679 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit (20+ min) | 123 | $9,235 | $52 |
| Return visit (30+ min) | 74 | $7,140 | $83 |
| New patient visit (45+ min) | 56 | $6,297 | $112 |
| New patient visit (30+ min) | 38 | $2,424 | $64 |
2022: 5 services
| Return visit (30+ min) | 94 | $9,275 | $83 |
| New patient visit (45+ min) | 78 | $8,279 | $106 |
| Short return visit (20+ min) | 88 | $6,918 | $52 |
| New patient visit (30+ min) | 19 | $1,365 | $72 |
| Short return visit | 14 | $375 | $25 |
2021: 6 services
| Return visit (30+ min) | 133 | $14,744 | $83 |
| New patient visit (45+ min) | 61 | $6,571 | $108 |
| Short return visit (20+ min) | 73 | $6,524 | $55 |
| Long return visit (40+ min) | 14 | $1,766 | $126 |
| Exam of ear using a microscope | 44 | $598 | $8 |
| Removal of impacted ear wax | 16 | $289 | $15 |
2020: 5 services
| Short return visit (20+ min) | 107 | $8,356 | $42 |
| New patient visit (30+ min) | 81 | $5,171 | $64 |
| Return visit (30+ min) | 61 | $3,943 | $65 |
| Exam of ear using a microscope | 54 | $757 | $8 |
| Removal of impacted ear wax | 20 | $744 | $29 |
2019: 5 services
| Short return visit (20+ min) | 94 | $6,683 | $44 |
| New patient visit (30+ min) | 109 | $6,644 | $61 |
| Return visit (30+ min) | 48 | $2,989 | $62 |
| Exam of ear using a microscope | 40 | $503 | $8 |
| Removal of impacted ear wax | 12 | $382 | $27 |
2018: 2 services
| New patient visit (30+ min) | 35 | $2,320 | $66 |
| Short return visit (20+ min) | 21 | $1,111 | $44 |
Medicaid work
$2,924 in 2024
Medicaid paid $2,924 for 64 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 64 | $2,924 |
| 2024 | 64 | 1 | 19 | $2,924 |
| 2023 | 113 | 2 | 17 | $2,687 |
| 2022 | 95 | 2 | 18 | $2,469 |
| 2021 | 42 | 2 | 15 | $1,236 |
| 2020 | 85 | 1 | 17 | $1,708 |
| 2019 | 50 | 1 | 17 | $1,352 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 89 | $2,051 |
| Return visit (30+ min) | 24 | $636 |
2022
| Return visit (30+ min) | 47 | $1,437 |
| Short return visit (20+ min) | 48 | $1,032 |
2021
| Short return visit (20+ min) | 29 | $779 |
| Return visit (30+ min) | 13 | $456 |
2020
| Short return visit (20+ min) | 85 | $1,708 |
2019
| Short return visit (20+ min) | 50 | $1,352 |
Drugs they prescribed that Part D paid
$6,938
Pharmacies billed $6,938 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 17% of their Part D prescriptions (22 of 128) in 2024. Above the middle of the specialty; the typical otolaryngology clinician is at 4%.
117 generic and fewer than 11 brand-name prescriptions · $6,938 in drug cost · 40 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ciprofloxacin-Dexamethasone | 16 | $2,428 | $116 |
| Ofloxacin | 13 | $660 | $44 |
| Cephalexin | 22 | $72 | $3 |
| Hydrocodone-Acetaminophen | 21 | $42 | $2 |
Year by year
| 2024 | 128 | 58 | 17% (22) | None | $6,938 |
| 2023 | 83 | 44 | 19% (16) | 14% | $5,070 |
| 2022 | 81 | 43 | None | None | $3,345 |
| 2021 | 109 | 45 | 12% (13) | None | $4,167 |
| 2020 | 112 | 42 | None | None | $3,234 |
| 2019 | 163 | 65 | 13% (21) | None | $6,358 |
| 2018 | 30 | 15 | None | None | $1,290 |
| 2017 | 17 | 12 | 71% (12) | 0% | $114 |
| 2016 | 26 | 23 | 89% (23) | None | $402 |
| 2015 | 38 | 29 | 61% (23) | None | $634 |
| 2014 | 17 | 16 | 77% (13) | 0% | $170 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Ciprofloxacin-Dexamethasone | 15 | $2,458 | $164 |
| Cephalexin | 18 | $121 | $7 |
| Hydrocodone-Acetaminophen | 15 | $50 | $3 |
2022: 1 drug
| Ofloxacin | 22 | $957 | $44 |
2021: 3 drugs
| Ofloxacin | 39 | $1,756 | $45 |
| Cephalexin | 15 | $76 | $5 |
| Hydrocodone-Acetaminophen | 13 | $60 | $5 |
2020: 1 drug
| Ofloxacin | 43 | $1,480 | $34 |
2019: 3 drugs
| Ofloxacin | 63 | $3,814 | $61 |
| Cephalexin | 24 | $147 | $6 |
| Hydrocodone-Acetaminophen | 18 | $99 | $5 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 12 | $84 | $7 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 20 | $231 | $12 |
2015: 1 drug
| Hydrocodone-Acetaminophen | 16 | $288 | $18 |
Money from drug and device companies
$412 in 2025
| 2025 | 2 | 12 | None | $412 |
| 2024 | 1 | 1 | None | $145 |
| 2023 | 1 | 2 | None | $122 |
| 2022 | 1 | 11 | None | $1,700 |
| 2021 | 1 | 1 | None | $89 |
| 2019 | 1 | 1 | None | $71 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Cochlear Americas | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode | $220 | 2 payments
|
| Medtronic | Midas Rex | $192 | 10 payments
|
See all 12 published payments
| Cochlear Americas | Meals · 2025-08-06 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode | $144 |
| Medtronic | Meals · 2025-04-06 | Midas Rex | $11 |
| Medtronic | Meals · 2025-04-06 | Midas Rex | $2 |
| Medtronic | Meals · 2025-04-06 | Midas Rex | $42 |
| Medtronic | Meals · 2025-04-06 | Midas Rex | $45 |
| Medtronic | Meals · 2025-04-06 | Midas Rex | $2 |
| Medtronic | Meals · 2025-04-05 | Midas Rex | $12 |
| Medtronic | Meals · 2025-04-05 | Midas Rex | $30 |
| Medtronic | Meals · 2025-04-05 | Midas Rex | $2 |
| Medtronic | Meals · 2025-04-05 | Midas Rex | $35 |
| Medtronic | Meals · 2025-04-05 | Midas Rex | $10 |
| Cochlear Americas | Meals · 2025-03-05 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode | $76 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $145
| DePuy Synthes Sales | Matrixorthognathic | $145 | 1 payment
|
2023: $122
| Cochlear Americas | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode | $122 | 2 payments
|
2022: $1,700
| Stryker | N/A | $1,700 | 11 payments
|
2021: $89
| Cochlear Americas | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode | $89 | 1 payment
|
2019: $71
| Smith+Nephew | Stravix | $71 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Cochlear Americas · A Post-Approval, Prospective, Nonrandomized, Single-Arm Multicenter Investigation To Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-Sided Deafness · 2024 | Their institution | $94,958 |
| Cochlear Americas · A Post-Approval, Prospective, Nonrandomized, Single-Arm Multicenter Investigation To Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-Sided Deafness · 2023 | Their institution | $62,963 |
| Cochlear Americas · A Post-Approval, Prospective, Nonrandomized, Single-Arm Multicenter Investigation To Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-Sided Deafness · 2022 | Their institution | $21,536 |
| Cochlear Americas · A Post-Approval, Prospective, Nonrandomized, Single-Arm Multicenter Investigation To Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-Sided Deafness · 2025 | Their institution | $12,660 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790075026
- Licence
- CA A123854California A123854: Current · expires 2028-10-31
- Trained
- University of California, San Diego School of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207YX0901X (207YX0901X); Otolaryngology (207Y00000X)
- Mailing address
- 801 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2011-04-07
- NPI last updated
- 2024-09-23
- NPI record certified
- 2024-09-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 801 Welch Rd, Palo Alto, CA, 94304